19.84
Adma Biologics Inc stock is traded at $19.84, with a volume of 4.19M.
It is down -2.07% in the last 24 hours and up +21.05% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$20.26
Open:
$19.77
24h Volume:
4.19M
Relative Volume:
1.68
Market Cap:
$4.73B
Revenue:
$426.45M
Net Income/Loss:
$197.67M
P/E Ratio:
24.20
EPS:
0.82
Net Cash Flow:
$110.10M
1W Performance:
-2.36%
1M Performance:
+21.05%
6M Performance:
-0.75%
1Y Performance:
+200.61%
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ADMA
Adma Biologics Inc
|
19.84 | 4.73B | 426.45M | 197.67M | 110.10M | 0.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-19-23 | Resumed | Raymond James | Strong Buy |
Oct-13-22 | Initiated | Mizuho | Buy |
Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
Jun-04-19 | Initiated | Jefferies | Buy |
Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
Feb-07-19 | Resumed | H.C. Wainwright | Buy |
Dec-11-17 | Reiterated | Maxim Group | Buy |
Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
Jul-25-16 | Reiterated | Maxim Group | Buy |
May-13-15 | Reiterated | Maxim Group | Buy |
Dec-08-14 | Initiated | Oppenheimer | Outperform |
Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest? - Yahoo Finance
Adma Biologics (ADMA) Stock Moves -0.15%: What You Should Know - Yahoo Finance
How IBD Stock Of The Day ADMA Biologics Shrugged Off Accounting Debacle For A Bullish Comeback - MSN
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy? - Zacks Investment Research
Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains? - MSN
Adma Biologics CEO Adam Grossman sells $397,320 in stock By Investing.com - Investing.com Australia
Adma Biologics CEO Adam Grossman sells $397,320 in stock - Investing.com
Here is What to Know Beyond Why ADMA Biologics Inc (ADMA) is a Trending Stock - Yahoo Finance
ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential - Seeking Alpha
Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know - Yahoo Finance
ADMA Stock Builds A Base As Profits Continue To Soar - MSN
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why - Yahoo Finance
Pulse of the Market: Wednesday’s 10 Top Performers - Insider Monkey
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
Why ADMA Biologics Inc. (ADMA) Went Up On Wednesday? - Yahoo Finance
Why Adma Biologics (ADMA) Outpaced the Stock Market Today - MSN
Will ADMA Biologics Stock Continue Its Momentum in 2025? - Yahoo Finance
Should You Invest in Adma Biologics (ADMA) Based on Bullish Wall Street Views? - Yahoo Finance
Adma Biologics (ADMA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
What's Driving the Market Sentiment Around ADMA Biologics? - Benzinga
Commit To Buy ADMA Biologics At $10, Earn 14% Using Options - Nasdaq
Bank of New York Mellon Corp Has $26.09 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Mutual of America Capital Management LLC Has $614,000 Stake in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook - MSN
Lost Money on ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Lisanti Capital Growth LLC Sells 59,565 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Mizuho lifts ADMA Biologics price target to $32, maintains Outperform - Investing.com
How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85% - MSN
ADMA Biologics Stock Climbs Amid Strong Earnings - TipRanks
ADMA Biologics (NASDAQ:ADMA) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Buy Rating Affirmed for ADMA Biologics Amid Transition to New Auditor and Growth Prospects - TipRanks
ADMA Biologics Earnings Call Highlights Strong Growth - TipRanks
ADMA Biologics Inc earnings beat by $0.31, revenue topped estimates - Investing.com Australia
BREAKING: Block & Leviton Investigating ADMA Biologics, - GlobeNewswire
BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed - EIN News
ADMA Biologics slips as 10-K delay overshadows earnings beat - MSN
ADMA Biologics stock slips on 10-K delay (ADMA:NASDAQ) - Seeking Alpha
ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2024 Earnings Call Transcript - Insider Monkey
ADMA Biologics Reports Strong 2024 Financial Performance - MSN
ADMA Biologics Inc (ADMA) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
ADMA Biologics Inc (ADMA) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):